Summary of findings 3: PLD with chemotherapy showed no clear difference in neurological (grade ≥ 3) compared with PLD alone (low certainty).
Summary of findings 1: PLD with chemotherapy showed no clear difference in overall severe adverse events (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).
Summary of findings 1: PLD with chemotherapy probably leads to higher anaemia (grade ≥ 3) compared with alternative combination chemotherapy (moderate certainty).
It is very uncertain whether summary of findings 1: PLD with chemotherapy changes hand‐foot syndrome (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).
It is very uncertain whether summary of findings 1: PLD with chemotherapy changes neurological (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).
Summary of findings 2: PLD alone showed no clear difference in overall survival (OS) compared with other conventional chemotherapy (moderate certainty).
It is very uncertain whether summary of findings 2: PLD alone changes progression‐free survival (PFS) compared with other conventional chemotherapy (very low certainty).
Chemotherapy with bevacizumab followed by maintenance bevacizumab showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
Chemotherapy with TKI followed by TKI maintenance probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).
Chemotherapy with TKI followed by TKI maintenance may leads to higher hypertension grade ≥ 3 compared with chemotherapy alone (low certainty).
The review found no eligible studies for this question.
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).
The review found no eligible studies for this question.
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… probably leads to lower any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Chemotherapy with bevacizumab followed by bevacizumab maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
It is very uncertain whether chemotherapy with bevacizumab followed by maintenance bevacizumab changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).